SHAREHOLDER ALERT: Weiss Law Reminds MLVF, SHBI, CBIO, and TA Shareholders About Its Ongoing Investigations

NEW YORK, April 27, 2023 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Malvern Bancorp, Inc. MLVF

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Malvern Bancorp, Inc. MLVF, in connection with the proposed acquisition of MLVF by First Bank ("First Bank"). Under the merger agreement, MLVF shareholders will receive 0.7733 shares of First Bank common stock, plus $7.80 in cash for each outstanding MLVF share, representing implied per-share consideration of $15.28 based upon First Bank's April 26, 2023 closing price of $9.67. If you own MLVF shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/mlvf

Shore Bancshares, Inc. SHBI

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Shore Bancshares, Inc. SHBI, in connection with the proposed merger of SHBI with The Community Financial Corporation. If you own SHBI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/shbi

Catalyst Biosciences, Inc. CBIO

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalyst Biosciences, Inc. CBIO, in connection with the proposed purchase of GNI Group Ltd.'s ("GNI") proprietary new chemical entity F351 ("F351"). This purchase will transfer the global rights to F351 (excluding Mainland China) to CBIO in consideration of 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock ("Series X") with economic rights equivalent to CBIO common stock to be paid for GNI's 65.18% interest of Beijing Continent, a China based commercial-stage pharmaceutical company marketing pirfenidone and having the rights to F351 in China. If you own CBIO shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/cbio

TravelCenters of America Inc. TA

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of TravelCenters of America Inc. TA in connection with the proposed acquisition of TA by BP p.l.c. Under the terms of the merger agreement, TA shareholders will receive $86.00 in cash for each share of TA common stock owned. If you own TA shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/ta

SOURCE Weiss Law